Autologous vs implant-based breast reconstruction: a PROs-focused review on radiotherapy impact

Background. The choice between Autologous Tissue Breast Reconstruction (ABR) and Implant-Based Reconstruction (IBR) is a fundamental decision in breast cancer survivorship. This choice is influenced by surgical evolution – specifically the shift to muscle-sparing techniques – and a modern focus on Patient-Reported Outcomes (PROs). This review critically compares these two modalities, focusing on long-term satisfaction, functional morbidity, and the definitive impact of radiotherapy (RT).
Methods. A structured literature review was conducted in accordance with PRISMA principles, utilizing MEDLINE and Embase databases from January 2015 to September 2025. The search strategy combined MeSH terms for “Mammaplasty”, “Patient Reported Outcome Measures” (BREAST-Q), and “Radiotherapy”. We prioritized systematic reviews, meta-analyses, and large comparative cohort studies (n = 60) that provided objective complication rates and subjective outcomes in both irradiated and non-irradiated settings.
Results. Evidence confirms that ABR provides statistically superior longterm satisfaction, psychosocial well-being, and sexual well-being ^1-3. This is driven by its biological integration and “like-with-like” properties. Conversely, IBR carries a high cumulative burden of re-operation (> 50% at 10 years) due to capsular contracture and aesthetic failure 4. Most critically, RT is the dominant predictor of failure, causing IBR failure rates exceeding 30%, whereas vascularized ABR flaps demonstrate robust resilience ^5,6.
Conclusions. While modern pre-pectoral IBR is a viable, low-morbidity option for select non-irradiated patients, ABR provides the most durable and psychologically favorable long-term outcome. The anticipated need for post-mastectomy radiation must be the primary driver in clinical decision-making, favoring autologous reconstruction as the gold standard in the irradiated setting.

INTRODUCTION

Mastectomy remains a necessary procedure for advanced breast carcinoma or prophylaxis. Subsequent breast reconstruction is recognized as an integral component of oncological recovery, profoundly influencing a patient’s physical integrity and psychosocial well-being ^7,8. In recent decades, the goal of reconstruction has evolved beyond mere volume replacement to sophisticated procedures aimed at maximizing aesthetic outcomes and long-term quality of life (QOL).

The history of Implant-Based Reconstruction (IBR) has been marked by a continuous effort to mitigate complications. Early reconstructions involved simple sub-muscular (sub-pectoral) placement, frequently associated with chronic pain and animation deformity ⁹. The paradigm shift occurred with the widespread adoption of Acellular Dermal Matrices (ADM) and the pre-pectoral approach, which has shown promise in reducing pectoral morbidity ⁷.

Simultaneously, Autologous Tissue Reconstruction (ABR) evolved from invasive pedicled flaps to microsurgical free tissue transfer. The Deep Inferior Epigastric Perforator (DIEP) flap has become the microsurgical gold standard, allowing for the transfer of skin and fat while completely sparing the rectus muscle ¹⁰.

Historically, success was defined by clinical metrics (flap survival, implant retention). However, the modern era prioritizes the patient’s perspective. Patient-Reported Outcomes (PROs), particularly those measured by the BREAST-Q, have become a primary endpoint ^7,8.

The choice between these two distinct categories – synthetic (IBR) versus biologic (ABR) – forms the core of contemporary reconstructive planning. Therefore, this comprehensive review aims to critically compare ABR and IBR from 2015 to 2025, specifically focusing on: (1) long-term PROs as captured by the BREAST-Q; (2) the critical impact of radiotherapy (RT); and (3) functional morbidity and cost-effectiveness. Additionally, we incorporate recent evidence regarding hybrid techniques ¹¹ and emerging implant-associated pathologies ¹² to provide updated evidence-based guidance.

MATERIALS AND METHODS

SEARCH STRATEGY AND DATA SOURCES

A systematic literature search was executed across MEDLINE (via PubMed) and Embase databases covering the period from January 1, 2015, to September 30, 2025. The search strategy employed a combination of Medical Subject Headings (MeSH) and free-text terms to ensure comprehensive coverage. The specific search string used was: (((“Mammaplasty”[MeSH] OR “Breast Reconstruction”) AND (“Autologous” OR “Flap” OR “Diep”)) AND (“Implant” OR “Prosthesis”) AND ((“Patient Reported Outcome Measures”[MeSH] OR “PROs”) OR (“BREAST-Q”)) AND (“Radiotherapy” OR “Radiation”)).

INCLUSION AND EXCLUSION CRITERIA

The screening process followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines (Suppl. Fig. 1).

• Inclusion criteria: (1) Comparative studies (Retrospective or Prospective), Systematic Reviews, and Meta-analyses; (2) Studies reporting quantitative PROs (specifically BREAST-Q) or objective complication rates; (3) Minimum follow-up of 12 months; (4) Sample size > 50 patients; (5) English language publications;
• Exclusion criteria: (1) Case reports, editorials, and expert opinions; (2) Studies focused solely on oncological outcomes without reconstructive data; (3) Animal studies; (4) Studies lacking separate data for irradiated cohorts.

DATA EXTRACTION

Data were extracted regarding study design, patient demographics, type of reconstruction (ABR vs IBR), follow-up duration, complication rates (stratified by RT), and PRO scores (Satisfaction with Breasts, Psychosocial Well-being).

RESULTS

STUDY SELECTION

The initial search yielded 1,124 citations. After duplicate removal and screening, 60 studies met the inclusion criteria. Key comparative studies included in this review are summarized in Table I.

PATIENT-REPORTED OUTCOMES (PROs)

Analysis of the BREAST-Q data consistently demonstrated a clear trend in favor of ABR in long-term domains (Tab. II).

• Satisfaction with breasts: mean scores were significantly higher in ABR groups compared to IBR groups in studies with long-term follow-up. A recent large-scale meta-analysis by Koziej et al. ³ confirmed this, showing significantly better aesthetic satisfaction (MD -8.51) and satisfaction with outcome (MD -6.56) for ABR.
• Psychosocial well-being: this domain also showed a persistent advantage for ABR, reflecting better integration of the reconstructed breast into the overall body image ^1,2.

LONG-TERM COMPLICATION RATES

The analysis of complications revealed divergent trajectories: IBR has a high cumulative risk of re-operation (often > 50% at 10 years), driven by Capsular Contracture ^4,15. Conversely, ABR is stable once established. Recent literature also highlights emerging concerns specific to implants, such as Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) and Squamous Cell Carcinoma (BIA-SCC), which, although rare, add to the long-term surveillance burden of IBR ¹².

THE IMPACT OF RADIOTHERAPY (RT)

RT proved to be the strongest predictor of failure, disproportionately affecting IBR. Studies consistently report reconstructive failure or implant removal rates exceeding 30% (up to 40% in irradiated cohorts) for IBR ^5,6,16. ABR displays notable resilience to radiation-induced fibrosis, maintaining tissue integrity with significantly lower failure rates ^5,6,16.

DISCUSSION

THE BIOLOGICAL AND PSYCHOSOCIAL RATIONALE FOR ABR SUPERIORITY

The data presented demonstrates a consistent superiority of ABR in long-term PROs ^1,2. The primary driver is the “like-with-like” principle. An autologous flap is living tissue that ages with the patient, gaining and losing weight naturally. In contrast, an implant is a static foreign body. This static nature is the root cause of declining satisfaction scores over time, as the reconstruction fails to harmonize with the patient’s natural aging process, leading to asymmetry ⁴.

THE DILEMMA OF CUMULATIVE COMPLICATIONS

Reconstructive planning involves a trade-off: IBR offers minimal initial surgical burden but carries a “lifetime burden” of maintenance. The complication burden of IBR is cumulative, with re-operation rates exceeding 50% at 10 years ⁴. ABR presents a “front-loaded” burden: it is microsurgically demanding with higher initial risk, but once established, the reconstruction is permanent and stable.

FUNCTIONAL OUTCOMES AND EVOLVING TECHNIQUES

Standard sub-pectoral IBR was linked to chronic pain and animation deformity ⁹. Modern pre-pectoral IBR, facilitated by ADM, eliminates muscle manipulation and significantly reduces this morbidity ¹⁸. However, ADMs are not without risk and have been linked to higher rates of seroma and infection ¹⁴. Furthermore, ABR trades pectoral morbidity for donor-site morbidity. The DIEP flap, while muscle-sparing, still carries a risk of abdominal wall weakness or bulging, requiring meticulous surgical technique ¹⁶.

DEVICE-RELATED ONCOLOGIC SAFETY

A crucial, modern consideration in the ABR vs. IBR debate is the oncologic safety of the device itself. While rare, Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) and the more recently described Breast Implant-Associated Squamous Cell Carcinoma (BIA-SCC) represent distinct entities ¹². These pathologies introduce a lifelong surveillance requirement for IBR patients that is absent in ABR. Recent guidelines suggest that while the absolute risk is low, patients must be informed of these potential long-term sequelae, further shifting the risk-benefit ratio in favor of autologous tissue for patients with a long life expectancy.

THE VETTING ROLE OF RADIOTHERAPY (RT)

The impact of Post-Mastectomy Radiation Therapy (PMRT) is the defining variable. PMRT induces a hostile, fibrotic microenvironment. In this setting, IBR failure rates soar to > 30% ^3,4. Autologous flaps, being vascularized tissue, bring their own blood supply and resist this fibrosis. The MROC prospective cohort studies ^10,11 found no significant difference in ABR failure rates between irradiated and non-irradiated patients, establishing ABR as the gold standard for the irradiated breast. Additionally, the performance of ADM in an irradiated field remains questionable, as RT compromises the neovascularization required for ADM integration ¹⁶.

COST-EFFECTIVENESS ANALYSIS

While ABR has higher initial costs due to operative time and hospitalization, it is more cost-effective over the long term. IBR incurs substantial costs from repeated revision surgeries. Analyses show that ABR provides more Quality-Adjusted Life Years (QALYs) and reaches a break-even point within the first decade ^20,21.

A comprehensive conceptual comparison of ABR versus IBR across multiple clinical and economic metrics is provided in Table III.

LIMITATIONS AND FUTURE DIRECTIONS

A critical appraisal reveals limitations in the evidence. The primary limitation is selection bias. Patients selected for ABR are often healthier (lower BMI, non-smokers) to qualify for microsurgery, while IBR cohorts often include patients with higher comorbidities. This baseline disparity confounds PROs and complication rates.

Furthermore, the field is evolving toward “Hybrid” approaches. Recent studies, such as the prospective analysis by Servillo et al. ¹⁸, demonstrate the efficacy of dual-plane techniques combining pre-pectoral implants with retro-pectoral fat grafting. Similarly, autologous options are expanding with techniques like the Fat-Augmented Latissimus Dorsi (FALD) flap ²¹. Future research must focus on randomized trials comparing these modern hybrid techniques against standard DIEP flaps in the irradiated setting. Recent narrative reviews and translational studies further outline future directions in autologous reconstruction and tissue engineering, including refinements in perforator flap design and scaffold-based approaches ^16,17.

CONCLUSIONS

The ideal reconstructive choice remains highly individualized. However, evidence strongly supports ABR for superior durability, aesthetic quality, and long-term subjective satisfaction (PROs). Clinical decision-making must be fundamentally driven by the patient’s anticipated need for post-mastectomy radiation.

Conflict of interest statement

The authors declare no conflict of interest.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author contributions

MV: A, D, DT, S, W

GI: DT

IV: DT

MB: DT

AP: D, S, DT

Abbreviations

A: conceived and designed the analysis

D: collected the data

DT: contributed data or analysis tool

S: performed the analysis

W: wrote the paper

Ethical considerations

This manuscript constitutes a critical review of existing published literature and does not involve any human participants or data acquired specifically for this study. Therefore, no Institutional Ethics Committee approval was required.

History

Received: November 11, 2025

Accepted: February 3, 2026

Figures and tables

Supplementary Figure 1. Study selection flow diagram (PRISMA 2020). Flowchart summarizing the identification, screening, eligibility, and inclusion of studies comparing autologous and implant-based breast reconstruction (2015-2025).

Table I. Summary of key comparative studies (2015-2025).

Author (year)	Study design	N (patients)	Comparison	Key findings
Koziej et al. (2023) 20	Meta-Analysis	55,455	ABR vs IBR	ABR superior in aesthetic satisfaction (p < 0.001) and outcome satisfaction. Cost higher for ABR initially
Toyserkani et al. (2020) 1	Meta-Analysis	2,896	ABR vs IBR	ABR significantly higher BREAST-Q scores in Satisfaction with Breasts (+8.8 points) and Sexual Well-being
McCarthy et al. (2017) 3	Prospective Cohort	2,247	ABR vs IBR (+/- RT)	RT caused 31.6% failure in IBR vs 5.1% in ABR. ABR satisfaction scores stable post-RT
Frisell et al. (2016) 4	Cohort Study	382	ABR vs IBR (+/- RT)	IBR+RT had highest complication rate (38.9%). ABR unaffected by RT in PROs
Eltahir et al. (2017) 2	Systematic Review	2,750	DIEP vs implant	DIEP superior in 4/5 BREAST-Q domains

Table II. Synthesis of mean BREAST-Q scores (weighted average).

BREAST-Q domain (scale 0-100)	Autologous (ABR) mean score	Implant-based (IBR) mean score	Mean difference	Clinical significance
Satisfaction with breasts	72.5	63.2	+9.3	Yes (> 5 points)
Psychosocial well-being	76.8	69.4	+7.4	Yes
Sexual well-being	58.2	49.5	+8.7	Yes
Physical well-being (chest)	78.0	74.5	+3.5	Borderline

Table III. Conceptual comparison of autologous (ABR) vs implant-based (IBR) reconstruction.

Metric	Autologous reconstruction (ABR)	Implant-based reconstruction (IBR)	Key evidence
Long-Term PROs	High & durable. Ages naturally with the patient	Moderate & declining. Static device, leads to asymmetry over time	[ 1 , 2 , 3 , 8 ]
Durability/re-intervention	High (permanent). “Front-loaded” surgical burden. Low lifetime re-operation risk	Low (maintenance required). “Lifetime burden.” High re-operation rate (> 50% at 10 years)	[ 4 , 15 ]
Initial surgical burden	High. Microsurgically complex, longer recovery	Low. Simpler, faster procedure	[ 10 ]
Functional morbidity	Donor site (abdominal wall weakness)	Recipient site (Pectoral dysfunction). Minimized by pre-pectoral	[ 18 , 9 , 10 ]
Radiotherapy resilience	High. Vascularized flap resists fibrosis	Low. High failure (30-40%), contracture, and extrusion	[ 5 , 6 , 16 ]
Cost-effectiveness	Cost-Effective (High initial, low long-term).	Less cost-effective (low initial, high cumulative)	[ 20 , 21 ]